Superworth

Lite Strategy EPS LITS

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$1.98
Latest quarter, Q4 FY26
−$0.38
Fiscal year 2026
−$1.98

Lite Strategy's earnings per share was −$1.98 over the twelve months to Jun 30, 2026.

In its latest quarter, Q4 FY26, it was −$0.38.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2026−$1.98n/a
FY2025−$2.39−190%
FY2024$2.67n/a
FY2023−$4.78n/a
FY2022−$10.12n/a
FY2021−$10.80n/a
FY2020−$10.20n/a
FY2019−$15.00n/a
FY2018−$18.40−1633%
FY2017$1.20n/a
FY2016−$12.20n/a
FY2015−$25.00n/a
FY2014−$27.00n/a
FY2013−$31.40n/a
FY2012−$67.80n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q4 FY26−$0.38n/a−$1.98
Q3 FY26−$0.66n/a−$2.00
Q2 FY26−$0.82n/a−$1.73
Q1 FY26−$0.12n/a−$1.31
Q4 FY25−$0.40n/a−$2.39
Q3 FY25−$0.39n/a−$4.75
Q2 FY25−$0.40n/a−$5.73
Q1 FY25−$1.20−114%−$6.99
Q4 FY24−$2.76n/a$2.67
Q3 FY24−$1.37n/a$3.92
Q2 FY24−$1.66−208%$2.97
Q1 FY24$8.46n/a$6.17

Against its peers

Companies in Drug Manufacturers - General nearest Lite Strategy's size, closest first, today.

CompanyEPS, 12 monthsGrowth
LITSLite Strategy−$1.98
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Lite Strategy

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.